Abstract
More than 70% active pharmaceutical ingredients (APIs), in the development pipeline, exhibit poor manufacturability (e.g., Isolation, flowability, tabletability) posing major challenges in the production of consistent product with desired performance1. Crystallisation is a key operation in the isolation of the majority of pharmaceuticals and has been demonstrated as a critical process to improve manufacturability of the drug.
Original language | English |
---|---|
Pages | 49-49 |
Number of pages | 1 |
Publication status | Published - 16 May 2022 |
Event | CMAC Annual Open Day 2022 - Glasgow, United Kingdom Duration: 16 May 2022 → 18 May 2022 |
Conference
Conference | CMAC Annual Open Day 2022 |
---|---|
Country/Territory | United Kingdom |
City | Glasgow |
Period | 16/05/22 → 18/05/22 |
Keywords
- active pharmaceutical ingredients
- manufacturability
- crystallisation